A number of studies have reported therapeutic benefit from inhibition of the TGF-β-ActRII-SMAD2/3 signaling axis in animal models of DMD [31, 36–41, 44, 45]. This evidence concerns the gene ACVR2A and Duchenne muscular dystrophy.